$93.800
0.000 (0.00%)收盤時
- High
- 96.950
- Open
- 93.100
- VWAP
- 94.26
- Vol
- 1.03M
- Mkt Cap
- 48.13M
- Low
- 92.036
- Amount
- 96.90M
- EV/EBITDA, TTM
- 0.22
Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH), a devastating disease impacting approximately 70,000 people in the United States and Europe. Oral imatinib also demonstrated statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in PAH patients. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. PAH is an orphan disease with unmet medical needs and is characterized by high pressure in the vessels transporting blood from the right side of the heart to the lungs.
估值指標
事件時間軸
資訊
8.504-21PRnewswireAerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals
4.504-09Business InsiderClosing Bell Movers: Futures sustaining gains after massive rebound
8.004-09PRnewswireAerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences
8.504-07NewsfilterAerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences
7.004-01PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TGI, AVTE, HEES, AMPY on Behalf of Shareholders
AVTE FAQ — answered by Alphio AI
Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH), a devastating disease impacting approximately 70,000 people in the United States and Europe. Oral imatinib also demonstrated statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in PAH patients. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. PAH is an orphan disease with unmet medical needs and is characterized by high pressure in the vessels transporting blood from the right side of the heart to the lungs. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。